4-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoic acid | 144051-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 4-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoic acid
• 英文别名: 4-[3-(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]-benzoic acid；4-[3-(2-Amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoic acid；4-[3-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoic acid
• CAS: 144051-63-8
• 化学式: C₁₆H₁₆N₄O₃
• 分子量: 312.328
• InChiKey: XGPPKKWZMFZGEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoic acid 在 N-甲基吗啉 、 sodium hydroxide 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 homoLY231514
  参考文献：
  名称：

  一种新型高效合成吡咯并[2,3-d]嘧啶抗癌药：Alimta（LY231514，MTA），均阿利姆他，TNP-351和一些芳基5-取代的吡咯并[2,3-d]嘧啶。

  摘要：

  已经通过一种新方法制备了Alimta以及均Alimta，Alimta的非桥接类似物以及TNP-351，该方法涉及将适当的1-硝基烯烃与2,6-二氨基-3H-嘧啶-4-酮进行迈克尔加成反应。或2,4,6-三氨基嘧啶，然后进行Nef反应，生成伯硝基迈克尔加合物。所得醛与嘧啶6-氨基的自发分子内环化反应产生相应的吡咯并[2,3-d]嘧啶。用相同的方法由上述嘧啶和硝基苯乙烯制备一系列以前未知的5-芳基吡咯并[2，3-d]嘧啶。已经发现，可以通过在含乙酸铵的乙酸中对芳基醛，硝基甲烷和6-氨基嘧啶的混合物进行超声处理而一步制备中间体伯硝基迈克尔加合物。

  DOI：

  10.1021/jo030248h
• 作为产物：
  描述：

  4-(4-羟基-1-丁炔基)苯甲酸甲酯 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 sodium acetate 、 甲基磺酰氯 、 三乙胺 、 pyridinium chlorochromate 作用下， 以 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 50.0 ℃ 、344.74 kPa 条件下， 反应 99.0h， 生成 4-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoic acid
  参考文献：
  名称：

  一种新型高效合成吡咯并[2,3-d]嘧啶抗癌药：Alimta（LY231514，MTA），均阿利姆他，TNP-351和一些芳基5-取代的吡咯并[2,3-d]嘧啶。

  摘要：

  已经通过一种新方法制备了Alimta以及均Alimta，Alimta的非桥接类似物以及TNP-351，该方法涉及将适当的1-硝基烯烃与2,6-二氨基-3H-嘧啶-4-酮进行迈克尔加成反应。或2,4,6-三氨基嘧啶，然后进行Nef反应，生成伯硝基迈克尔加合物。所得醛与嘧啶6-氨基的自发分子内环化反应产生相应的吡咯并[2,3-d]嘧啶。用相同的方法由上述嘧啶和硝基苯乙烯制备一系列以前未知的5-芳基吡咯并[2，3-d]嘧啶。已经发现，可以通过在含乙酸铵的乙酸中对芳基醛，硝基甲烷和6-氨基嘧啶的混合物进行超声处理而一步制备中间体伯硝基迈克尔加合物。

  DOI：

  10.1021/jo030248h

文献信息

• [EN] PROCESS FOR THE PREPARATION OF PYRROLO[2,3-D]PYRIMIDINES<br/>[FR] PROCEDE DE PREPARATION DE PYRROLO[2,3-D]PYRIMIDINES
  申请人：UNIV PRINCETON

  公开号：WO2000011004A1

  公开（公告）日：2000-03-02

  4(3H)-X-7H-Pyrrolo[2,3-d]pyrimidines in which X is =O or =NH are prepared by (i) treating a 6-amino-4(3H)-X-pyrimidine with a unsubstituted or substituted 1-nitroalk-1-ene to yield a 6-amino-4(3H)-X-pyrimidine which is substituted in the 5-position by a 1-nitroalk-2-yl group; (ii) converting the 5-(1-nitroalk-2-yl)-6-amino-4(3H)-X-pyrimidine to the corresponding 5-(1-oxoalk-2-yl)-6-amino-4(3H)-X-pyrimidine; and (iii) removing the elements of water from the 5-(1-oxoalk-2-yl)-6-amino-4(3H)-X-pyrimidine to effect cyclization. A typical embodiment involves treating 2,6-diamino-4(3H)-pyrimidone with 1-nitro-4-(4-ethoxycarbonylphenyl)-I-butene to yield 1-nitro-2-(2,6-diamino 4(3H)-oxopyrimidin-5-yl)-4-(4-ethoxycarbonylphenyl)butane which is then treated sequentially with base and acid, without isolation of the intermediate aldehyde, to form 4-[2-(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid, a valuable known chemical intermediate for the preparation of N-[4-2-(2-hydroxy-4-amino-7H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl}benzoyl]glutamic acid.

  本发明涉及一种制备4(3H)-X-7H-吡咯并[2,3-d]嘧啶的方法，其中X = O或= NH，包括以下步骤：(i)用非取代或取代的1-硝基烯烃处理6-氨基-4(3H)-X-嘧啶，得到在5-位上被1-硝基烷基取代的6-氨基-4(3H)-X-嘧啶；(ii)将5-(1-硝基烷基-2-基)-6-氨基-4(3H)-X-嘧啶转化为相应的5-(1-氧代烷基-2-基)-6-氨基-4(3H)-X-嘧啶；(iii)从5-(1-氧代烷基-2-基)-6-氨基-4(3H)-X-嘧啶中除去水分以进行环化。典型实施例包括用1-硝基-4-(4-乙氧羰基苯基)-1-丁烯处理2,6-二氨基-4(3H)-嘧啶，得到1-硝基-2-(2,6-二氨基4(3H)-氧代嘧啶-5-基)-4-(4-乙氧羰基苯基)丁烷，然后依次用碱和酸处理而不分离中间体醛，形成4-[2-(2-氨基-4(3H)-氧代-7H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸，这是制备N-[4-2-(2-羟基-4-氨基-7H-吡咯并[2,3-d]-嘧啶-5-基)乙基}苯甲酰]谷氨酸的有价值的已知化学中间体。
• Condensed heterocyclic oligoglutamate derivatives, their production and pharmaceutical compositions containing them
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0492316A1

  公开（公告）日：1992-07-01

  A novel compound of the formula: wherein a ring A stands for an optionally substituted 5-membered ring; B stands for an optionally substituted divalent cyclic or chain group; either one of Q¹ and Q² stands for N and the other stands for N or CH; X stands for an amino group, hydroxyl group or mercapto group; Y stands for H, halogen atom or a group bonded through C, N, O or S; Z stands for a straight-chain divalent group having 2 to 5 atoms constituted of optionally substituted carbon atoms or constituted of optionally substituted carbon atoms and one optionally substituted hetero-atom; COOR¹ and COOR² independently stand for an optionally esterified carboxyl group; n denotes an integer of 2 to 6; and R¹ may be different in each of n repeating units, or their salts and it is useful as a therapeutic drug for tumor in mammals.

  一种新颖的式化合物： 其中环 A 代表任选取代的五元环；B 代表任选取代的二价环状或链状基团；Q¹ 和 Q² 中的一个代表 N，另一个代表 N 或 CH；X 代表氨基、羟基或巯基；Y 代表 H、卤素原子或通过 C、N、O 或 S 键合的基团；Z 代表具有 2 至 5 个原子的直链二价基团，这些原子由任选取代的碳原子构成，或由任选取代的碳原子和一个任选取代的杂原子构成；COOR¹ 和 COOR² 分别代表任选酯化的羧基；n 表示 2 至 6 的整数；R¹ 在每个 n 个重复单元或其盐中可能不同，可用作哺乳动物的肿瘤治疗药物。
• Discovery of 5-Substituted Pyrrolo[2,3-<i>d</i>]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity
  作者：Shermaine Mitchell-Ryan、Yiqiang Wang、Sudhir Raghavan、Manasa Punaha Ravindra、Eric Hales、Steven Orr、Christina Cherian、Zhanjun Hou、Larry H. Matherly、Aleem Gangjee

  DOI：10.1021/jm401328u

  日期：2013.12.27

  We synthesized 5-substituted pyrrolo[2,3-d]pyrimidine antifolates (compounds 5-10) with one-to-six bridge carbons and a benozyl ring in the side chain as antitumor agents. Compound 8 with a 4-carbon bridge was the most active analogue and potently inhibited proliferation of folate receptor (FR) alpha-expressing Chinese hamster ovary and KB human tumor cells. Growth inhibition was reversed completely or in part by excess folic acid, indicating that FR alpha is involved in cellular uptake, and resulted in S-phase accumulation and apoptosis. Antiproliferative effects of compound 8 toward KB cells were protected by excess adenosine but not thymidine, establishing de novo purine nucleotide biosynthesis as the targeted pathway. However, 5-aminoimidazole-4-carboxamide (AICA) protection was incomplete, suggesting inhibition of both AICA ribonucleotide formyltransferase (AICARFTase) and glycinamide ribonucleotide formyltransferase (GARFTase). Inhibition of GARFTase and AICARFTase by compound 8 was confirmed by cellular metabolic assays and resulted in ATP pool depletion. To our knowledge, this is the first example of an antifolate that acts as a dual inhibitor of GARFTase and AICARFTase as its principal mechanism of action.
• US6066732
  申请人：——

  公开号：——

  公开（公告）日：——
• Exploitation of a new route to fused pyrroles: Synthesis of TNP-351, homo-MTA and 5-arylpyrrolo[2,3-]pyrimidines
  作者：Edward C. Taylor、Bin Liu

  DOI：10.1016/s0040-4039(99)00677-2

  日期：1999.5

  We have developed a new methodology for the construction of pyrrolo[2,3-d]pyrimidines that involves Michael addition of 2,6-diamino-4(3 (H) under bar)-pyrimidinone or 2,4,6-triaminopyrimidines to nitroolefins, followed by a Nef reaction of the resulting adduct to form an intermediate aldehyde that spontaneously cyclizes to the fused pyrrole ring, This methodology has been exploited in a new synthesis of TNP-351, and for the first reported preparation of homo-MTA and of a series of 5-arylpyrrolo[2,3-(d) under bar]pyrimidines. (C) 1999 Elsevier Science Ltd. All rights reserved.